B2BINPAY
14.2.2024 09:22:28 CET | Business Wire | Press release
B2BinPay, the trusted blockchain-backed payment platform, has officially released its version 19 update to the public. This upgrade boasts many enhancements, including state-of-the-art instant swaps and expanded support for various blockchains. As always, B2BinPay remains dedicated to providing a seamless and secure platform for all cryptocurrency transactions.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240214263094/en/
B2BinPay v19 goes live with instant swaps and expanded blockchain support (Photo: Business Wire)
New Instant Swaps and Competitive VWAP-powered Rates
Swaps have become a preferred strategy for managing digital assets due to the direct exchange of cryptocurrencies between different addresses. This is a contrarian approach to conventional exchanges, which use the order books system for asset trading.
With B2BinPay, clients can easily access instant swaps without navigating through complicated order books and comparing prices across different venues. This is made possible with the Volume-Weighted Average Price (VWAP) tool, which automatically selects the best available price from multiple centralised platforms based on transaction volume.
In addition, the use of swaps by B2BinPay clients eliminates two blockchain commission costs, namely, the transaction to the centralised exchange and the transaction back to the B2BinPay wallet, which adds flexibility and cost-effectiveness in dealing with digital assets.
Instant swaps can be accessed through the dedicated Swaps Tab on the platform's front-end menu, along with separate wallets for each crypto asset.
Commission-Free Wallet Funding, Smooth Swapping Process
The latest release introduces a customised top-up process for swap wallets tailored to different user categories. Those with digital wallets can now take advantage of swift transactions for instant fund transfers, while owners of blockchain wallets benefit from on-chain transactions that offer both transparency and security through recorded data on the blockchain. It is crucial to note that topping up must be done in the wallet's designated currency.
In addition, users can enjoy a commission-free top-up process from their B2BinPay accounts. Note that blockchain wallets will still incur a minimal fee for on-chain transactions.
New Blockchain Network Integration: Avalanche and Polygon
B2BinPay's latest release has integrated support for two in-demand blockchains, Polygon and Avalanche. This integration brings an array of stablecoin transaction options to the platform, including popular choices like USDT, USDC, DAI, FRAX, TUSD, and EUROC on new networks.
Known for its scalability and minimal transaction fees, Polygon is a popular choice for a large number of crypto users. In comparison, Avalanche shines with its high throughput and rapid processing times, providing a powerful platform for speedy transfers.
Final Remarks
B2BinPay continues to push the boundaries of crypto processing with their latest version 19 release. This update offers clients even more flexibility, allowing them to access more blockchains and cryptocurrencies and make instant exchanges with swap wallets.
The team isn't stopping there – they are actively working on reducing fees to make their services even more cost-effective for all clients in future releases. This dedication to continuous improvement demonstrates B2BinPay's commitment to meeting the evolving needs of businesses and startups alike.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240214263094/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Acceleronix, IDEMIA Secure Transactions and Orange Announce Flexible, Single-SKU Manufacturing with Quantum-Safe IFPP4.11.2026 16:44:00 CET | Press release
One SKU. Every market. Connectivity decided at the end of production. Live at electronica 2026. Orange, one of the world’s leading telecom operators, has joined the global quantum-safe In-Factory Profile Provisioning (IFPP) program, jointly launched by Acceleronix and IDEMIA Secure Transactions at MWC Barcelona in February. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104070181/en/ Acceleronix, IDEMIA Secure Transactions and Orange announce flexible, single-SKU manufacturing with quantum-safe IFPP The program enables device makers to build a single product for every market and connect it to the Orange network before it leaves the factory. Acceleronix and IDEMIA Secure Transactions will demonstrate the solution live at electronica 2026, the international electronics trade fair, at Messe München, Hall C2, Stand 601, from 10 to 13 November. Most connected devices share the same weak spot: provisioning and testing on the pr
U.S. FDA Grants Priority Review to BeOne Medicines’ BRUKINSA Combination in First-Line Mantle Cell Lymphoma4.11.2026 15:13:00 CET | Press release
If approved, BRUKINSA plus rituximab would be the first and only chemotherapy-free, BTK inhibitor-based regimen for adult patients with previously untreated mantle cell lymphomaApplication supported by Phase 3 MANGROVE data, showing a 43% reduction in the risk of progression or death versus bendamustine plus rituximabFull MANGROVE results to be presented during the Plenary Scientific Session at the 68th American Society of Hematology Annual Meeting BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review to the supplemental New Drug Application (sNDA) for BRUKINSA® (zanubrutinib) in combination with rituximab for the treatment of adult patients with previously untreated mantle cell lymphoma (MCL). The application is supported by data from the pivotal Phase 3 MANGROVE study, in which this chemotherapy-free regimen significantly reduced the risk of dis
Rimini Street Awarded CANUT Third-Party Maintenance Framework Agreement4.11.2026 15:00:00 CET | Press release
This framework agreement provides all entities subject to the French Public Procurement Code with simplified access to a support alternative enabling them to control their costs, preserve their freedom of technological choice and free themselves from vendor-imposed upgrade cycles Rimini Street, Inc. (Nasdaq: RMNI), the Software Support and Agentic AI ERP Company™ and the leading third-party support provider for Oracle, SAP and VMware software, today announced that it had been selected as the awardee of the third-party support service lots (TMA) by CANUT, the French public purchasing center specializing in digital technology and telecommunications. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104431817/en/ Rimini Street Awarded CANUT Third-Party Maintenance Framework Agreement Eligible public organizations subject to the French Public Procurement Code can now benefit from Rimini Street services for their Oracle, SAP, VMw
Incyte to Present New Data Highlighting Progress Across its Hematology Portfolio at ASH 20264.11.2026 15:00:00 CET | Press release
New data in myeloproliferative neoplasms (MPNs) will include INCA033989, Incyte’s first-in-class, mutant calreticulin (mutCALR)-targeted monoclonal antibody, in first-line myelofibrosis (MF); and preclinical findings for Incyte’s next-generation mutCALR- and JAK2V617F-targeted compoundsUpdated results for INCA033989 in second-line MF and second-line essential thrombocythemia (ET) will build on previously presented datasetsLong-term Phase 1/2 data further characterize the potential of latarcibart (VGA039), an investigational Protein S-targeting antibody, as prophylaxis in adolescents and adults with von Willebrand disease (VWD)More than 30 abstracts will highlight progress across Incyte’s broader hematology portfolioIncyte will host an investor event and webcast on Saturday, December 12, 2026 from 7:30 – 9:00 p.m. CT (8:30 – 10:00 p.m. ET) Incyte (Nasdaq:INCY) today announced that new data highlighting progress across its hematology portfolio will be presented across more than 30 abstra
Zenitar Announces Initiation of International Randomized Study of Flonoltinib Maleate in Patients with Myelofibrosis and Related American Society of Hematology 2026 Meeting Presentations4.11.2026 15:00:00 CET | Press release
Chengdu Zenitar Biomedical Technology Co., Ltd. (Zenitar) is developing flonoltinib maleate (FM), a first-in-class oral JAK2/FLT3/CDK6 inhibitor for myeloproliferative neoplasms (MPNs), including myelofibrosis (MF) and polycythemia vera (PV). Zenitar launched randomized Phase 2 FM-MF-02 (NCT07750574) in the US, Canada and Brazil to select Phase 3 dose for JAKi-naïve and refractory MF. Randomized FMF-02 (NCT06457425) met its week-24 endpoints: superior SVR35 and TSS50 with FM 50/100mg versus ruxolitinib; previous data presented orally at ASH24 (#486) and ASH25 (#908). ASH 2026 presence covers FMF-02 long-term follow-up (oral presentation, #411, December 12, 4:30pm) and refractory PV Phase 2 data (poster, #3765, December 13, 6pm), both in Session 634. “Over the 15 years since the initial FDA approval of Ruxolitinib, JAKi have markedly improved the prognosis of many patients with MF. The long-term data show significant room for improvement for this key therapeutic class in terms of both e
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom